Ocular Therapeutix (OCUL) Institutional Ownership
13F filers reported holding 13.6% of Ocular Therapeutix (OCUL) shares as of Sep 30, 2026, across 94 filers.
- Held by 13F filers
- 13.6%
- Sep 30, 2026
- 13F filers
- 94
- quarter ended Sep 30, 2026
- 13F value
- $229.1M
- 29.9M shares
- Quarter's fund flow
- Mild accumulation
- 13 new · 13 closed
Is the smart money (institutions and insiders) accumulating or distributing? One lagging input, not a buy signal.
| Date | Name | Role | Type | Shares | Price** | SEC filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | Sherif Riad | director | Acquired · Grant / award | 28,000 | — | ↗ |
| Nov 6, 2026 | Sherif Riad | director | Acquired · Grant / award | 88,000Stock Option (Right to Buy) | — | ↗ |
| Oct 8, 2026 | Anderman Todd | Chief Legal Officer | Disposed · Open-market sale | 11,984 | $7.29 | ↗ |
| Oct 2, 2026 | Kaiser Peter | Chief Development Officer | Disposed · Open-market sale | 9,990 | $7.05 | ↗ |
| Oct 2, 2026 | Heier Jeffrey S. | Chief Scientific Officer | Disposed · Open-market sale | 10,869 | $7.05 | ↗ |
| Aug 31, 2026 | Notman Donald | Chief Operating Officer | Disposed · Open-market sale | 1,099 | $10.24 | ↗ |
| Aug 25, 2026 | Dugel Pravin | See Remarks | Disposed · Gift | 50,092 | — | ↗ |
| Aug 25, 2026 | Dugel Pravin | See Remarks | Acquired · Gift | 50,092 | — | ↗ |
| Aug 24, 2026 | Kaiser Peter | Chief Development Officer | Disposed · Open-market sale | 3,035 | $10.77 | ↗ |
| Aug 24, 2026 | Nayak Sanjay | Chief Strategy Officer | Disposed · Open-market sale | 1,897 | $10.78 | ↗ |
| Aug 24, 2026 | Heier Jeffrey S. | Chief Scientific Officer | Disposed · Open-market sale | 3,296 | $10.78 | ↗ |
| Aug 24, 2026 | Dugel Pravin | See Remarks | Disposed · Open-market sale | 21,649 | $10.77 | ↗ |
| Jun 16, 2026 | Dugel Pravin | See Remarks | Disposed · Gift | 50,092 | — | ↗ |
| Jun 16, 2026 | Dugel Pravin | See Remarks | Acquired · Gift | 50,092 | — | ↗ |
| Jun 10, 2026 | Warden Charles M | director | Acquired · Grant / award | 14,000 | — | ↗ |
| Jun 10, 2026 | Warden Charles M | director | Acquired · Grant / award | 44,000Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | Graves Adrienne L | director | Acquired · Grant / award | 14,000 | — | ↗ |
| Jun 10, 2026 | Graves Adrienne L | director | Acquired · Grant / award | 44,000Stock Option (Right to Buy) | — | ↗ |
| Jun 10, 2026 | Robins Jason Shand | Chief Financial Officer | Acquired · Grant / award | 15,441 | — | ↗ |
| Jun 10, 2026 | Robins Jason Shand | Chief Financial Officer | Acquired · Grant / award | 14,024Stock Option (Right to Buy) | — | ↗ |
* Holdings as reported for Sep 30, 2026, 49 days old; funds file up to 45 days after each quarter-end, so the newest complete quarter runs 45 to 135 days behind.
** A price of “—” marks an option exercise, RSU vest or a filing without a usable per-share price, not a $0 trade.
Common questions
How much of Ocular Therapeutix do institutions hold?
13F filers reported holding 13.6% of Ocular Therapeutix's shares as of Sep 30, 2026, across 94 filers.
How many 13F filers hold Ocular Therapeutix?
Ocular Therapeutix was held by 94 13F filers as of Sep 30, 2026.
Not investment advice.

